Quintiles

Quintiles undertakes genomic “pre-profiling” feasibility study

Friday, September 27, 2013 10:22 AM

CRO Quintiles has announced plans to improve the development of biomarker-targeted therapies through a novel approach that promotes the genomic “pre-profiling” of cancer patients. Quintiles is undertaking a study with the participation of U.S. Oncology Research, supported by McKesson Specialty Health and The U.S. Oncology Network, to explore the operational feasibility and clinical benefits of an upfront approach to the genomic profiling of tumors from metastatic colorectal cancer (mCRC) patients. The study will investigate how pre-profiling and genomic sequencing data may support physician treatment decisions, including the identification of appropriate clinical trials for patients.

More... »

Quintiles closes Novella Clinical acquisition

Monday, September 23, 2013 01:40 PM

Global CRO Quintiles has completed its previously announced acquisition of Novella Clinical, a full-service CRO focused primarily on emerging oncology as well as medical devices and diagnostics.

More... »

Quintiles receives Computerworld Data+ Editor's Choice Award

Thursday, August 29, 2013 01:00 PM

CRO Quintiles has been recognized for its pioneering work creating big data solutions that help pharmaceutical organizations improve their probability of success throughout the drug development process, with a Computerworld Data+ Editor's Choice Award for its Quintiles Infosario platform.

More... »

Quintiles to acquire Novella Clinical

Wednesday, August 14, 2013 01:22 PM

CRO Quintileshas signed an agreement to acquire Novella Clinical, a full-service CRO focused primarily on emerging oncology customers as well as those in the medical device and diagnostics sectors. 

More... »

inVentiv Health Clinical expands executive team

Friday, August 9, 2013 02:02 PM

CRO inVentiv Health Clinical has appointed Dawn Anderson president of phase II-IV development, Martin Birkhofer chief medical officer and Richard Shimota chief financial officer.

More... »

Quintiles Infosario wins Informatica Innovation Award

Monday, June 10, 2013 11:44 AM

Quintiles received the 2013 Informatica Innovation Award for “Enterprise Data Integration” through the Quintiles Infosario solution, to integrate and master both clinical research and healthcare data across numerous institutions and at a scale never before accomplished in the biopharmaceutical industry.

More... »

Quintiles completes IPO of 27,236,841 shares of common stock

Wednesday, May 15, 2013 09:18 AM

Quintiles completed its initial public offering of 27,236,841 shares of its common stock at a price to the public of $40.00 per share.

More... »

Quintiles prices IPO at $40 per share

Thursday, May 9, 2013 11:40 AM

Quintiles has announced the pricing of its initial public offering of 23,684,210 shares of its common stock at a price to the public of $40.00 per share. The shares of Quintiles common stock are expected to begin trading on the New York Stock Exchange under the single-letter symbol "Q” on May 9, 2013.  

More... »

Quintiles wins Best CRO Award at World Vaccine Congress 2013

Friday, April 26, 2013 11:06 AM

For the second consecutive year, Quintiles has been named Best Clinical Research Organization (CRO) in the Vaccine Industry Excellence (ViE) Awards. Presented at the World Vaccine Congress, the awards recognize and celebrate individuals, organizations and initiatives which have made significant contributions over the past 12 months.

More... »

Quintiles selects BRANY as U.S. Prime site

Monday, April 22, 2013 11:48 AM

BRANY (Biomedical Research Alliance of New York) has been designated a Quintiles Prime Site. The designation will advance BRANY’s participation in clinical trials by providing improved access to new industry-sponsored clinical trials.

More... »